These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 15751501)

  • 1. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
    Viale PH
    Clin J Oncol Nurs; 2005 Feb; 9(1):77-84. PubMed ID: 15751501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced nausea and vomiting: state of the art in 2006.
    Schwartzberg L
    J Support Oncol; 2006 Feb; 4(2 Suppl 1):3-8. PubMed ID: 16499138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the management of chemotherapy-induced nausea and vomiting.
    Viale PH
    J Infus Nurs; 2006; 29(5):283-92. PubMed ID: 17035890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
    Oo TH; Hesketh PJ
    Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M; Tsukuda M
    Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
    Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
    Navari RM
    Expert Opin Pharmacother; 2009 Mar; 10(4):629-44. PubMed ID: 19284365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting.
    Osorio-Sanchez JA; Karapetis C; Koczwara B
    Intern Med J; 2007 Apr; 37(4):247-50. PubMed ID: 17388865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use.
    Wickham R
    J Support Oncol; 2010; 8(2 Suppl 1):10-5. PubMed ID: 20629453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
    Sugimori Y; Ota T; Ujihira T; Ishiguro T; Ogishima D
    J Obstet Gynaecol Res; 2017 Sep; 43(9):1454-1459. PubMed ID: 28952201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.
    Celio L; Denaro A; Canova S; Gevorgyan A; Bajetta E
    Tumori; 2008; 94(4):447-52. PubMed ID: 18822676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.